Covalent inhibitors: a rational approach to drug discovery
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
In this review we provide a brief historic overview of covalent inhibitors and summarize recent advances focusing on developments in the last decade. Applications in challenging targets and future perspectives are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures













Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past 30 years, the rational design of covalent drugs has garnered increased interest, and covalently targeting non-conserved amino acids to increase selectivity has become commonplace2,5.”
From Advances in covalent drug discovery (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Covalent drugs also exhibit impressive performance in selective targeting,521 potentially providing novel inhibitory approaches for kinases such as CK1, which have previously only been targeted with non-covalent ATP competitive inhibitors.522”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [521]
The cited source says what the claim attributes to it.
In the citing paper
“Covalent inhibitors, which form covalent bonds with their target proteins, rely on the specificity and stability of these interactions to exhibit superior potency, selectivity, and duration of action. This mechanism offers patients a convenient therapeutic option.521,565”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [521]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
PENICILLIN-BINDING PROTEINS AND THE MECHANISM OF ACTION OF BETA-LACTAM ANTIBIOTICS
Waxman, D. J., & Strominger, J. L. (1983) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.52.070183.004141 · Cited by 721
Gehringer, M., & Laufer, S. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01153 · Cited by 714
Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0314 · Cited by 620 · cited 1×
“In 2013, Walter et al.13 showed that a novel covalent inhibitor, CO-1686, inhibits a drug-resistance mutant of T790M EGFR.”
Background
Cited by
Items 301–400 of 403
Alimardan, Z., Kashfi, K., Abbasi, M., & Khodarahmi, G. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130401 · Cited by 1
Li, R., Shi, Q., Zhu, M., Cao, W., Tao, Y., & Shen, L. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100239 · Cited by 1
Advancing label-free screening technologies to enhance drug discovery efficiency
Cheng, R., & Liu, C. (2026) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2026.2622372 · Cited by 1
“Covalent inhibitor drugs have gained renewed interest due to their enhanced efficacy, sustained target engagement, and ability to bind shallow pockets [110–112].”
Chemical Space Exploration of a Database of Covalent Binders in the PDB
Velasco-Saavedra, M. A., Mar-Antonio, E., Colorado-Pablo, L. F., Santos‐Contreras, M. Á., Flores-León, C. D., Carreón-Escalante, M., Sánchez-Maza, S., Ambrosio-Huerta, A., Goode‐Romero, G., Medina‐Franco, J. L., et al. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c00846 · Cited by 1
Covalent inhibition of New Delhi metallo-β-lactamases NDM-1 and NDM-5 by 3-bromopyruvate
Bradley, J. K., Calvopiña, K., Moyo, S. J., Shore, E., Nambala, P., Hong, W. D., Schofield, C. J., & Roberts, A. P. (2026) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlag177 · Cited by 1
Synthesis of Amino-Acid-Based Nitroalkenes
Gerogianni, V.-E., Koutoulogenis, G. S., Gerokonstantis, D. T., & Kokotos, G. (2022) · Organics · doi:10.3390/org3020011 · Cited by 1
“However, today it is estimated that about 30% of the marketed drugs are covalent inhibitors [1,2].”
Synthesis and Characterization of Reversible Covalent HDAC4 Inhibitors
Frühauf, A., Wolff, B., Schweipert, M., & Meyer‐Almes, F. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2788-4_14 · Cited by 1
Narjes, F., Pairaudeau, G., & Petrović, D. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00682 · Cited by 1
Taype-Huanca, K., Osorio, M. I., Inostroza, D., Leyva‐Parra, L., Ruíz, L. M., Valderrama-Negrón, A., Alvarado-Huayhuaz, J. A., Yáñez, O., & Tiznado, W. (2024) · Biophysica · doi:10.3390/biophysica4020013 · Cited by 1
“It enables the strategic positioning of noncovalent interaction points and the incorporation of electrophilic moieties designed to form covalent bonds with the biological target [63].”
BackgroundCovalent Flexible Peptide Docking in Drug Discovery: Current Challenges and Potential Interventions
Lafifi, Z., Bjij, I., & Soliman, M. E. S. (2024) · Innovation Discovery · doi:10.53964/id.2024015 · Cited by 1
Synthesis of electrophile-tethered preQ 1 analogs for covalent attachment to preQ 1 RNA
Flemmich, L., & Micura, R. (2025) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.21.35 · Cited by 1
Design of Highly Specific Structural Fragments for Filtering Compounds with Undesirable Activities
Савосина, П. И., Druzhilovskiy, D. S., Filimonov, D. A., & Poroikov, V. (2025) · Biomedical Chemistry Research and Methods · doi:10.18097/bmcrm00303 · Cited by 1
de Rosa, M., Nonnis, S., & Aliverti, A. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.09.008 · Cited by 1
Molitor, M., Menge, A., Mandel, S., George, S., Müller, S., Knapp, S., Hofmann, B., Steinhilber, D., & Häfner, A. (2024) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-024-03019-7 · Cited by 2
Innovative high throughput medicinal chemistry
Hadian, M. (2023) · doi:10.33612/diss.613687248 · Cited by 1
Jewell, C. P., Perciaccante, A. J., Brown, K., Maity, T. K., Dinan, J. C., Bissa, M., Rahman, M. A., Franchini, G., Appella, D. H., & Jenkins, L. M. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.28.721345 · Cited by 1
Awoonor‐Williams, E. (2021) · ChemRxiv · doi:10.26434/chemrxiv-2021-zpp2j
Inhibition studies on the human 20S proteasome: molecular insights from a computational approach
Serrano-Aparicio, N. (2022) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · doi:10.6035/14122.2022.684242
Wong, K. K. V., Gazali, A. M., Zamri, N. B., Rullah, K., & Aluwi, M. F. F. M. (2022) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416522300024
Moitessier, N., Labarre, A., Stille, J. K., Patrascu, M. B., Martins, A., & Pottel, J. (2021) · ChemRxiv · doi:10.26434/chemrxiv.14568921
Moitessier, N., Labarre, A., Stille, J. K., Patrascu, M. B., Martins, A., & Pottel, J. (2021) · doi:10.33774/chemrxiv-2021-d94vz-v2
Aziz, U. B. A., Bermúdez, M., Mieth, M., Saoud, A., Rudolf, T., Arkona, C., Böttcher, C., Ludwig, K., Hocke, A. C., Wolber, G., et al. (2022) · ChemRxiv · doi:10.26434/chemrxiv-2022-fx0d2
Covalent drug discovery exploiting the new warheads
Ojida, A. (2022) · Folia Pharmacologica Japonica · doi:10.1254/fpj.22052
A kovalens enziminhibíció számításos kémiai jellemzése
Mihalovits, L. M., Ferenczy, G. G., & Keserű, G. M. (2022) · Magyar kémiai folyóirat, Kémiai közlemények · doi:10.24100/mkf.2022.03-4.150
Identification of Covalent Ligands – from Single Targets to Whole Proteome
Ngo, C., Ekanayake, A. I., & Zhang, C. (2023) · Israel Journal of Chemistry · doi:10.1002/ijch.202200105 · Cited by 1
Liu, Y. A., Wang, Z., Hu, W., Ma, M., Yang, H. X., & Wen, K. (2023) · Springer eBooks · doi:10.1007/978-3-031-39404-1_4
Molecular Origin of Novichok Nerve AgentsPreprint
Verhellen, J. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-w1ngh
Current Trends in the Development and Biochemistry of Drugs
Nisar, M., Dilawar, M., Javed, A., Rafiq, M., Arfan, M., Rahman, S. U., Niaz, K., & Nisar, M. F. (2024) · Springer eBooks · doi:10.1007/978-3-031-50989-6_13
Structural Considerations and Chemistry of PROTACs
Wahi, A., Jadhav, H. R., Thakur, S., Dev, S., Mohanty, P., & Jain, P. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_3
Targeted anticancer pre-vinylsulfone covalent inhibitors of carbonic anhydrase IXPreprint
Vaškevičius, A., Baronas, D., Leitāns, J., Kvietkauskaitė, A., Rukšėnaitė, A., Manakova, E., Toleikis, Z., Kaupinis, A., Kazāks, A., Gedgaudas, M., et al. (2024) · eLife · doi:10.7554/elife.101401.1
Covalency in PROTACs: Mechanisms and applications
Geiger, T. M., & Nowak, R. P. (2024) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2024.10.001 · Cited by 1
Covalent Inhibitors of MAP Kinases
De, S. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-75682-5_5
Targeted anticancer pre-vinylsulfone covalent inhibitors of carbonic anhydrase IXPreprint
Vaškevičius, A., Baronas, D., Leitāns, J., Kvietkauskaitė, A., Rukšėnaitė, A., Manakova, E., Toleikis, Z., Kaupinis, A., Kazāks, A., Gedgaudas, M., et al. (2024) · eLife · doi:10.7554/elife.101401.2 · Cited by 1
Jermusek, F. A., & Webb, L. J. (2024) · Biochemistry · doi:10.1021/acs.biochem.4c00313
Alam, S., Shehzad, A., Ayesha, B., & Rahman, H. U. (2025) · Zoo botanica. · doi:10.55627/zoobotanica.002.03.0998
Advancements in Structural Basis of Covalent Inhibitors Targeting SARS-CoV-2 Essential Proteins
Fatima, I., Alshabrmi, F. M., Alkhayl, F. F. A., Qasim, M., Shafqat, A., Batool, S., Jawad, M. T., Qamar, M. T. U., & Rehman, A. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673323348241208080419
Kučerová-Chlupáčová, M. (2025) · Česká a slovenská farmacie · doi:10.36290/csf.2025.001
Chen, E. P. (2025) · Wiley eBooks · doi:10.1002/9781119650263.ch11
Singh, A., Xu, S.-H., Tsai, Y.-D., Yang, Z., Tang, H.-J., Tsai, Y.-J., Tsai, H.-Y., Yuan, C.-W., Chen, C., Thitithanyanont, A., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108646
Gao, M., Hu, W., Meng, D., Yao, P., Yang, S., Tong, Y., Wang, L., Zhang, Y., Wang, Q., Ji, J., et al. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.101060
“Approximately 30% of marketed drugs function as covalent inhibitors (24), and these have been effectively utilized in the treatment of various diseases.”
O’Hare, S., Tolmachova, K. A., & Bode, J. W. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00281
Meden, A., Brazzolotto, X., Dias, J., Stojan, J., Knez, D., & Gobec, S. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111841
Tricarbonyl Rhenium‐Based PROTACs Degrade the SARS‐CoV‐2 Mpro Protease
Luo, L., Lu, Y., Meng, H., Lin, W., Lu, K., Wang, J., Wang, J., Xiong, Y., Mao, Z., & Xia, W. T. (2025) · Chemistry - A European Journal · doi:10.1002/chem.202503042
Modelling Covalent Inhibitors of Protein Kinases Using Deep Learning Techniques
Niranjan, R., & Sukumar, N. (2025) · IEEE India Council International Subsections Conference (INDISCON) · doi:10.1109/indiscon66021.2025.11253673
“Sutanto et al. [19] discovered that about 30% of pharmaceuticals on the market react through covalent mechanisms, which have their origins in the late 18th century.”
Faris, A., Ibrahim, I. M., kamaly, O. A., Saleh, A., & Elhallaoui, M. (2023) · Research Square · doi:10.21203/rs.3.rs-3011914/v1
Tyrosine Kinase as the Therapeutic Target for Neurodegenerative Diseases
Mandal, N., Bej, A., Das, A., & Nandi, A. (2025) · IGI Global eBooks · doi:10.4018/979-8-3373-4627-4.ch010
Pham, K. H. T., Nguyen, H. V. T., & Nguyễn, T. K. (2025) · Tạp chí Khoa học Đại học Đông Á · doi:10.59907/daujs.4.4.2025.535
“Among them, saxagliptin (SAX) and vildagliptin (VIL) act as reversible covalent inhibitors, forming an imidate adduct with the Ser630 residue at the DPP4 catalytic site, which enhances potency and minimizes side effects compared to non-covalent inhibitors (Nabeno et al., 2013; Sutanto et al., 2020).”
Jain, N., & Iwaoka, M. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1768658
Carbamoyl fluorides as serine hydrolase inhibitors: a case study on FphI from Staphylococcus aureus
Randall, G., Meden, A., Rutledge, M. T., Prestreši, L., Hrast, M., Chen, S., Zdovc, I., Gobec, S., Knez, D., & Fellner, M. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109834 · Cited by 2
Development of small molecules modulating the activity of the nucleoside kinase dCK
Yaala, K. B. (2021) · theses.fr (ABES) · doi:10.70675/749d80bcze0abz4780za87czd786c1617d69
Discovery and characterization of a covalent inhibitor of New Delhi metallo β-lactamase
Rivera, D. D., Schroeder, J. M., Walker, J. N., Bashyal, A., Iyer, A. G., Lee, R. H., Melkonian, T. R., Brodbelt, J. S., Fast, W. L., & Whitman, C. P. (2026) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2026.110805
Bottlinger, M., Morici, M., Fajardo-Ruiz, E., Gantner, I., Brameyer, S., Isselstein, M., Berger, M. J., Wilson, D. N., Jung, K., & Sieber, S. A. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.5c01018
“22,23 In the search for antibacterial natural products bearing electrophilic moieties and lacking functional characterization, we came across Ianthelliformisamine A − C ( Ian-A − C ), brominated aryl-polyamines with a benzylic Michael acceptor moiety (Figure 1a).”
SuFEx‐Enabled Reprogramming of Flavonoids for Selective α‐Glucosidase Covalent Inhibition
Guo, F., Zhang, L., Wang, M., Du, Y., Zhang, T., Chen, H., Sun, J., Yu, Y., He, Z., An, J., et al. (2026) · Advanced Science · doi:10.1002/advs.75869
“This approach has been successfully applied to several clinically important enzymes, including Bruton’s tyrosine kinase and epidermal growth factor receptor [ 10, 11 ].”
Trans -selective semireduction of activated alkynes via phosphine redox catalysis
Ye, Z., Wang, M., Li, H., Su, W., Shang, Y., & Jie, X. (2026) · Chemical Communications · doi:10.1039/d6cc02689c
Light‐Controlled Modulation of 15‐Lipoxygenase‐1 Regulates Intestinal Inflammatory Signaling
Louka, A., Kalaitzaki, E.-E., Panousis, A., Bonoras, S., Livas, C. G., Froudakis, G. E., Drygiannakis, I., Damianaki, A., Kolios, G. C., Valatas, V., et al. (2026) · Angewandte Chemie · doi:10.1002/ange.3141559
Light‐Controlled Modulation of 15‐Lipoxygenase‐1 Regulates Intestinal Inflammatory Signaling
Louka, A., Kalaitzaki, E.-E., Panousis, A., Bonoras, S., Livas, C. G., Froudakis, G. E., Drygiannakis, I., Damianaki, A., Kolios, G. C., Valatas, V., et al. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.3141559
“Covalent strategies can further enhance durability and selectivity, yet at the cost of reversibility and dynamic control [5, 6].”
Xue, J., Xue, J., You, Y., Lu, J., Zhang, H., Wang, K., Yang, Z., Wang, J., & Deng, Y. (2026) · New Journal of Chemistry · doi:10.1039/d6nj02257j · Cited by 1
Souza, B. C., Froes, T. Q., Castilho, M. S., & Leite, F. H. A. (2026) · Chemical Papers · doi:10.1007/s11696-026-05292-5
Covaleda, D., Vizarraga, D., Upadhyay, T., Zhu, J., Abegg, D., Pequerul, R., Hugo, M., Adibekian, A., Fita, I., Parés, X., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.14.738401
“Covalent enzyme inhibition has re-emerged as a powerful strategy in chemical biology and drug discovery because durable target engagement can produce sustained pharmacological effects beyond compound exposure (17,18).”
Zhang, X., Wang, K., Meng, R., Zeng, Q., Li, Y., Ma, X., Liu, Y., Shi, Y., Zh, Y., Zhang, N., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.07.031
Khyluk, D., Demchuk, O. M., Holota, S. M., Otto‐Ślusarczyk, D., Struga, M., Burdan, F., & Wujec, M. (2026) · Molecules · doi:10.3390/molecules31152612
“Thus, for therapeutic targeting of sulfatases, especially in chronic diseases, non-covalent inhibitors may represent a safer and more controllable alternative to irreversible covalent compounds, although the safety profile of a drug is determined by multiple factors [22,23].”
Bhattacharyya, M. (2026) · Springer eBooks · doi:10.1007/978-981-92-1167-8_27
Nodola, P., Molefe, P. S. S., Tseki, P. F., & Gumede, N. J. (2026) · Molecules · doi:10.3390/molecules31162877
Chemical Biology 2025: Highlights From the Ch/Bi145 Course at Caltech
Ashton-Rickardt, G. P., Chung, D. K., Corman, S. A., Gilbert, M. S., Green, Z. B., Hengartner, E. R., Hou, J., Kang, D., Konsler, J. K., Kuleshova, I. D., et al. (2026) · ChemBioChem · doi:10.1002/cbic.70485
“Currently, many highly successful pharmaceuticals including ibrutinib, osimertinib, and sotorasib are covalent inhibitors [3, 4].”
Targeted protein degradation: mechanistic diversity, therapeutic expansion, and clinical translation
Wang, C., Guo, Z., Liu, Y., Gao, Q., Wang, Q., Liu, Y., & Liu, Y. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127323 · Cited by 1
Hsu, C.-P., Desgagné, M., Rössler, S. L., Grob, N. M., Farquhar, C. E., Loas, A., Jensvold, Z. D., Baddock, H. T., Bratkowski, M. A., Nile, A. H., et al. (2026) · Chemical Science · doi:10.1039/d6sc05323h
“1,2 Their advantages, such as prolonged residence time and reduced reliance on high a ffi nity for e ffi - cient binding, render TCIs well-suited for modern therapeutic challenges.”
A lysis-derived PMSF and orthovanadate oxidant defines a distinct cysteine-engagement profile
Schaffer, B. E., Nam, J. S., Cohen, C. A., Mesaros, C., Myers, R. W., Baxt, L. A., Wellen, K. E., Cantley, L. C., Dephoure, N., Snyder, N. W., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.08.005
High‐Throughput Technologies for Targeted Covalent Drug Discovery: Recent Advances and Perspectives
Yu, H., Wang, X., Wang, X., & Yin, Y. (2026) · Chemistry - A European Journal · doi:10.1002/chem.71680
Luo, M., Ma, L., Luo, G., & Xiang, H. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118506
Innovation-driven drug discovery: Frontier exploration and breakthrough
Du, S., Hu, X., Clercq, E. D., Liu, X., & Zhan, P. (2026) · The Innovation Medicine · doi:10.59717/j.xinn-med.2026.100262
CHARMM-GUI Covalent Ligand Docker as a Web-Based Molecular Docking Platform for Covalent Ligands
Kong, L., Suh, D., & Im, W. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c02343
Determinants of cysteine coverage by chemoproteomicsPreprint
Riziotis, I. G., Wilders, H., Cairoli, A., Lambert, H., Dark, J., Biggs, G. S., Cawood, E. E., McCarthy, W., Nightingale, L., Magariños, M. P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.12.758458
Long, Y., Yu, T., Sun, J., Hu, J., & Bai, W. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6c07262
Dahab, M. A., Ashoub, A. F., Ali, R. A., Sallam, A. S., & Mayhoub, A. S. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119449
BindingDB (2026) · UC San Diego · doi:10.7270/q22n575t
BindingDB Entry 50023438: Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?
BindingDB (2026) · UC San Diego · doi:10.7270/q2h136xb
BindingDB Entry 50015871: Advanced approaches of developing targeted covalent drugs.
BindingDB (2023) · UC San Diego · doi:10.7270/q2df6w53
BindingDB Entry 50017151: Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.
BindingDB (2023) · UC San Diego · doi:10.7270/q2bv7mpd
BindingDB (2026) · UC San Diego · doi:10.7270/q2rv0tkm
BindingDB Entry 50021046: Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
BindingDB (2025) · UC San Diego · doi:10.7270/q2891bg0
BindingDB Entry 50015590: Metalloaminopeptidases of the Protozoan Parasite
BindingDB (2023) · UC San Diego · doi:10.7270/q2bg2szc
BindingDB Entry 50021670: Covalent ligands of nuclear receptors.
BindingDB (2025) · UC San Diego · doi:10.7270/q2m90f9q
Metadata
- Authors
- Sutanto, F., Konstantinidou, M., & Dömling, A.
- Affiliations
- University of Groningen (NL)
- Corresponding author
- Dömling, Alexander
- Venue
- RSC Medicinal Chemistry
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2020
- Volume
- 11
- Issue
- 8
- Pages
- 876-884
- ISSN
- 2632-8682 (ISSN-L)
- PMC
- PMC7557570
- OpenAlex
- W3038238188
- Cited by
- 389
- References
- 27
- Citations by year
- 2026: 50 · 2025: 75 · 2024: 72 · 2023: 64 · 2022: 75 · 2021: 48 · 2020: 5
- FWCI
- 19.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- RSC Medicinal Chemistry (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
- Funders
- National Institutes of Health (2R01GM097082-05)
- KWF Kankerbestrijding (10504)
- Lembaga Pengelola Dana Pendidikan
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- covalent inhibitors, drug discovery, off-target toxicity, cancer drug targets
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.